ReviewFrontiers in epidemiology2025
The urgent need for newer drugs in routine HIV treatment in Africa: the case of Ghana.
Review in Frontiers in epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Mutation-Tolerant Inhibition of HIV-1 Integrase Strand Transfer by Secondary Metabolites from the Endophytic FungusMicroorganisms · 2026Article
- JAK-STAT and IL-17 pathway dysregulation underlies persistent immune dysfunction in ART-experienced people living with HIV in Ghana.Frontiers in immunology · 2026Article
- Prolonged Exposure to Antiretroviral Therapy and Risk of Developing Hypertension Among HIV-Infected Clinic Attendees: A Pilot Study in Rural Eastern Cape Province, South Africa.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antiretroviral therapy (ART) has tremendously improved the quality of life of people living with HIV (PLWH). Through rigorous scientific research and development, newer, more effective, and less toxic antiretrovirals (ARVs) have been developed and are available to PLWH in high-income countries (HICs). Although Africa accounts for more than two-thirds of the global burden of HIV/AIDS, this large population does not readily have access to these newer and more effective ARVs. In some instances, new ARVs become available to PLWH in Africa over a decade after they have been approved for use by the Food and Drug Authorities (FDAs) in HICs. Since 2010, 35 new drug entities have been approved; of those, only 3 are in common use in Ghana and most of Sub-Saharan Africa. To achieve the 2030 goal of ending HIV/AIDS as a global health epidemic, it is critical to ensure equity in access to newer and effective ARVs across all regions, including Africa, where the majority of PLWH reside. We highlight here the urgent need to make newer ARVs available in Africa to ensure the realization of the Global End AIDS by 2030 goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.